The big problem is i think they still havent conducted phase 1 trials in any firm. This means they dont even have indication of safety in healthy humans as yet. As per recent announcement that trial jhas been initiated but results are still a year away and until we get that i guess we cant even consider trialling against disease. Compassionate access might give results but apparently that is difficult to get useable data from as it is just given to save a life and not as part of any trial. It is good that it shows the capabilities of 327 but realistically doesnt seem to be anything that will produce cash in the short term, unless it can make things look goid enough to attract a buy out? Not sure if that is on directors radar or if they want to take it all the way themselves.
RCE Price at posting:
36.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)